Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITY-FXI in Healthy Adults and Adults with Thrombophilic Mutations or History of VTE
NCT07430397Phase 1Recruiting
- Sponsor
- City Therapeutics
- Start
- Jan 2026
- Primary completion
- Mar 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CITY-FXI in venous thromboembolism (VTE), factor V Leiden thrombophilia (FVL) and prothrombin G20210A mutation (PTM) (6 arms), sponsored by City Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events at Day 360. Started Jan 2026; status: recruiting.
02
Drugs
CITY-FXI
03
Conditions
venous thromboembolism (VTE)factor V Leiden thrombophilia (FVL)prothrombin G20210A mutation (PTM)
Beyond the preview
Go deeper on NCT07430397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07430397.